Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Commercial innovation: reshaping the life sciences commercia...

Gabrielle Pastore discusses the importance of commercial innovation in both large, and small, life sciences companies. As the pace and scope of our industry continues to change at lightning speed, one thing remains clear – innovation is...

Articles

Spotlight on...leprosy

Nicolette and Dr Rao provide a spotlight on leprosy, explaining the symptoms, risks and available treatments. They also share their thoughts on how pharma can best support patients in the future. What is Leprosy (Hansen’s Disease)? Leprosy is mainly a disease of the nerves and skin, caused by...

Articles

The future’s bright, the future’s...digital

In our digital focus month, we speak with research team leader Ryan McGuire, about some of the US and global digital trends and how he thinks pharma can mitigate the risks when implementing digital marketing strategies. It’s fair to say it has taken pharma awhile to jump on the digital bandwagon. But it jumped and now here...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access